法律人 LawPlayer logo

資料由法律人 LawPlayer整理提供·EU law / curated by LawPlayer from EUR-Lex

Regulation

Commission Implementing Regulation (EU) 2023/948 of 12 May 2023 authorising the placing on the market of 6′-Sialyllactose sodium salt produced by derivative strains of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

CELEX
Implementing Regulation (EU) 2023/948
Date of document
Articles
5
Source
EUR-Lex
Article 1

1.   6′-Sialyllactose sodium salt produced with derivative strains of Escherichia coli BL21(DE3) is authorised to be placed on the market within the Union.

6′-Sialyllactose sodium salt produced with derivative strains of Escherichia coli BL21(DE3) shall be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470.

2.   The Annex to Implementing Regulation (EU) 2017/2470 is amended in accordance with the Annex to this Regulation.

Article 2

Only the company Chr. Hansen A/S  ( 15 ) is authorised to place on the market within the Union the novel food referred to in Article 1, for a period of five years from 4 June 2023, unless a subsequent applicant obtains an authorisation for that novel food without reference to the scientific data protected pursuant to Article 3 or with the agreement of Chr. Hansen A/S.

Article 3

The scientific data contained in the application file and fulfilling the conditions laid down in Article 26(2) of Regulation (EU) 2015/2283 shall not be used for the benefit of a subsequent applicant for a period of five years from the date of entry into force of this Regulation without the agreement of Chr. Hansen A/S.

Article 4

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

Schedules & Appendices

ANNEX

ANNEX

The Annex to Implementing Regulation (EU) 2017/2470 is amended as follows:

(1)

in Table 1 (Authorised novel foods), the following entry is inserted in alphabetical order:

Authorised novel food

Conditions under which the novel food may be used

Additional specific labelling requirements

Other requirements

Data Protection

‘ 6’-Sialyllactose (‘6 ′ -SL’) sodium salt

(produced by derivative strains of E. coli BL21(DE3))

Specified food category

Maximum levels

The designation of the novel food on the labelling of the foodstuffs containing it shall be ‘6′-Sialyllactose sodium salt’.

The labelling of food supplements containing 6′-Sialyllactose (6′-SL) sodium salt shall bear a statement that

(a)

they should not be consumed by children under 3 years of age;

(b)

they should not be consumed if other foods containing added 6′-sialyllactose sodium salt are consumed the same day.

Authorised on 4 June 2023. This inclusion is based on proprietary scientific evidence and scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283.

Applicant: “Chr. Hansen A/S”, Bøge Allé 10-12, 2970 Hoersholm, Denmark. During the period of data protection, the novel food 6′-Sialyllactose sodium salt is authorised for placing on the market within the Union only by Chr. Hansen A/S unless a subsequent applicant obtains authorisation for the novel food without reference to the proprietary scientific evidence or scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283 or with the agreement of “Chr. Hansen A/S”.

End date of the data protection: 4 June 2028.’

Infant formula as defined under Regulation (EU) No 609/2013

0,70 g/L in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Follow-on formula as defined under Regulation (EU) No 609/2013

0,70 g/L in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Processed cereal-based foods for infants and young children and baby foods for infants and young children as defined under Regulation (EU) No 609/2013

0,70 g/L or 0,70 g/kg in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Milk based drinks and similar products intended for young children

0,70 g/L in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer

Foods for special medical purposes for infants and young children as defined under Regulation (EU) No 609/2013

In accordance with the particular nutritional requirements of the infants and young children for whom the products are intended but in any case not higher than 0,70 g/L or 0,70 g/kg in the final product ready for use, marketed as such or reconstituted as instructed by the manufacturer.

Foods for special medical purposes as defined under Regulation (EU) No 609/2013 excluding foods for infants and young children

In accordance with the particular nutritional requirements of the persons for whom the products are intended

Food Supplements as defined in Directive 2002/46/EC, for the general population, excluding infants and young children

1,8 g/day

(2)

in Table 2 (Specifications), the following entry is inserted in alphabetical order:

Authorised novel food

Specification

‘6’ -Sialyllactose (‘6’-SL’) sodium salt

(produced by derivative strains of E. coli BL21(DE3))

Description:

6'-Sialyllactose (6′-SL) sodium salt is a purified, white to off-white powder or agglomerate produced by a microbial process and contains limited levels of lactose, 6'-sialyl-lactulose, and sialic acid.

Definition:

Chemical name: N-Acetyl-α-D-neuraminyl-(2→6)-β-D-galactopyranosyl-(1→4)-D-glucose, sodium salt

Chemical formula: C 23 H 38 NO 19 Na

Molecular mass: 655,53 Da

CAS No: 157574-76-0

Source: Two genetically modified strains (a production strain and an optional degradation strain) of Escherichia coli BL21(DE3)

Characteristics/Composition:

6′-Sialyllactose sodium salt (% of dry matter): ≥ 90,0 % (w/w)

6′-Sialyl-lactulose (% of dry matter): ≤ 3,0 % (w/w)

D-Lactose (% of dry matter): ≤ 5,0 % (w/w)

Sialic acid (% of dry matter): ≤ 2,0 % (w/w)

N-acetyl-D-glucosamine (% of dry matter): ≤ 3,0 % (w/w)

Sum of other carbohydrates (% of dry matter) a : ≤ 5,0 % (w/w)

Moisture: ≤ 9,0 % (w/w)

Ash: ≤ 8,5 % (w/w)

Residual protein: ≤ 0,01 % (w/w)

Sodium: ≤ 4,2 % (w/w)

Contaminants:

Arsenic: ≤ 0,2 (mg/kg)

Aflatoxin M1: ≤ 0,025 (μg/kg)

Microbiological criteria:

Standard plate count: ≤ 1 000 CFU/g

Enterobacteriaceae: ≤ 10 CFU/g

Salmonella spp.: Absence in 25 g

Yeast and mould: ≤ 100 CFU/g

Cronobacter spp. : Absence in 10 g

Residual endotoxins: ≤ 10 EU/mg

a Sum of other carbohydrates = 100 (% (w/w) of dry matter) – 6'-Sialyllactose sodium salt (% (w/w) of dry matter) – quantified carbohydrates (% (w/w) of dry matter) – Ash (% (w/w) of dry matter); CFU: Colony Forming Units; EU: Endotoxin Units’

5 articles

Cite this act

Commission Implementing Regulation (EU) 2023/948 of 12 May 2023 authorising the placing on the market of 6′-Sialyllactose sodium salt produced by derivative strains of Escherichia coli BL21(DE3) as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance) (EUR-Lex). Retrieved via LawPlayer, https://lawplayer.com/eu/act/32023R0948

© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.

EU-EurLex-Reuse-2011-833

本頁資料來源:EUR-Lex·整理提供:法律人 LawPlayer· lawplayer.com